Detalle Publicación

Integration of immunotherapy into treatment of cervical cancer: recent data and ongoing trials

Autores: Monk, B. J. (Autor de correspondencia); Enomoto, T.; Kast, W. M.; McCormack, M.; Tan, D. S. P.; Wu, X.; González Martín, Antonio
Título de la revista: CANCER TREATMENT REVIEWS
ISSN: 0305-7372
Volumen: 106
Páginas: 102385
Fecha de publicación: 2022
Cervical cancer constitutes a significant health burden for women globally. While most patients with early-stage disease can be cured with radical surgery or chemoradiotherapy, patients with high-risk locally advanced disease or with recurrent/metastatic disease have a poor prognosis with standard treatments. Immunotherapies are a rational treatment for this HPV-driven cancer that commonly expresses programmed cell death ligand-1. Before 2021, pembrolizumab was the only United States Food and Drug Administration-approved immunotherapy in cervical cancer, specifically for the second-line recurrent or metastatic (r/m) setting. In late 2021, the antibody-drug conjugate tisotumab vedotin was approved for second-line r/m cervical cancer and pembrolizumab com-bined with chemotherapy +/- bevacizumab was approved for first-line r/m disease based on results from KEYNOTE-826. Moreover, with at least 2 dozen additional immunotherapy clinical trials in the second-line and first-line r/m setting, as well as in locally advanced disease, the treatment landscape for cervical cancer may eventually encounter a potential paradigm shift. Pivotal trials of immunotherapies for cervical cancer that were recently approved or with the potential for regulatory consideration through 2024 are reviewed. As immuno-therapy has the opportunity to establish new standards of care in the treatment of cervical cancers, new bio-markers to identify the ideal patient populations for these therapies may also become important. However, issues with access, affordability, and compliance in low-and middle-income countries are anticipated.